Profile data is unavailable for this security.
About the company
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
- Revenue in USD (TTM)2.84m
- Net income in USD-7.20m
- Incorporated2005
- Employees23.00
- LocationDare Bioscience Inc3655 Nobel Dr Ste 260SAN DIEGO 92122-1050United StatesUSA
- Phone+1 (858) 926-7655
- Fax+1 (302) 636-5454
- Websitehttps://www.darebioscience.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 17.76m | 91.00 | -- | 0.6735 | -- | 0.47 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
TherapeuticsMD Inc | 996.00k | -4.83m | 19.14m | 1.00 | -- | 0.6918 | -- | 19.22 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
Tonix Pharmaceuticals Holding Corp | 12.46m | -149.01m | 20.14m | 103.00 | -- | 0.0336 | -- | 1.62 | -110.99 | -110.99 | 6.16 | 4.28 | 0.1083 | 0.8436 | -- | 120,951.50 | -129.55 | -59.46 | -157.22 | -65.92 | 21.59 | -- | -1,196.12 | -5,126.73 | 0.7181 | -- | 0.1678 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
Cyclo Therapeutics Inc | 1.13m | -20.74m | 21.52m | 8.00 | -- | -- | -- | 19.00 | -0.9104 | -0.9104 | 0.0474 | -0.1785 | 0.242 | 0.4002 | 13.16 | 141,553.80 | -443.08 | -132.22 | -- | -215.17 | 91.56 | 90.37 | -1,831.29 | -1,114.04 | 0.4283 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
BioXcel Therapeutics Inc | 2.40m | -107.83m | 22.41m | 74.00 | -- | -- | -- | 9.33 | -3.56 | -3.56 | 0.074 | -1.84 | 0.0234 | 0.5941 | 3.87 | 32,472.97 | -104.93 | -74.57 | -150.29 | -84.06 | 43.07 | -- | -4,487.39 | -32,300.74 | 2.25 | -10.10 | 3.59 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
DH Enchantment Inc | 100.00 | -173.19k | 22.99m | 1.00 | -- | -- | -- | 229,878.60 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
KALA BIO Inc | 0.00 | -38.72m | 24.65m | 43.00 | -- | 1.79 | -- | -- | -13.95 | -13.95 | 0.00 | 2.98 | 0.00 | -- | -- | 0.00 | -60.45 | -57.83 | -78.16 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.36 | 0.7174 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
Polypid Ltd | 0.00 | -24.70m | 24.90m | 59.00 | -- | 10.61 | -- | -- | -9.65 | -9.65 | 0.00 | 0.3337 | 0.00 | -- | -- | 0.00 | -107.89 | -76.92 | -164.39 | -89.61 | -- | -- | -- | -- | -- | -24.21 | 0.8425 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
Incannex Healthcare Inc | 12.00k | -18.46m | 27.88m | 9.00 | -- | 2.24 | -- | 2,322.97 | -1.14 | -1.14 | 0.0007 | 0.7067 | 0.0003 | -- | 0.0024 | 1,333.33 | -48.51 | -130.12 | -54.36 | -148.24 | -- | -- | -153,833.30 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
Dare Bioscience Inc | 2.84m | -7.20m | 28.20m | 23.00 | -- | 10.56 | -- | 9.93 | -1.07 | -1.07 | 0.3579 | 0.3126 | 0.1213 | -- | 3.85 | 123,462.20 | -30.76 | -109.51 | -191.39 | -246.26 | 0.8477 | -- | -253.60 | -1,104.55 | -- | -- | 0.00 | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
Natural Alternatives International, Inc. | 113.80m | -7.22m | 28.33m | 296.00 | -- | 0.3431 | -- | 0.2489 | -1.23 | -1.23 | 19.38 | 13.32 | 0.7676 | 3.96 | 9.52 | 384,445.90 | -4.87 | 2.33 | -5.61 | 2.80 | 6.03 | 14.24 | -6.34 | 2.06 | 1.59 | -10.21 | 0.1326 | 0.00 | -26.11 | -3.82 | -386.16 | -- | -10.75 | -- |
Acasti Pharma Inc | 0.00 | -11.45m | 31.53m | 32.00 | -- | 0.5312 | -- | -- | -1.22 | -1.22 | 0.00 | 5.85 | 0.00 | -- | -- | -- | -16.04 | -31.68 | -16.57 | -33.95 | -- | -- | -- | -56,271.43 | -- | -37.80 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
Equillium Inc | 42.62m | -8.32m | 33.09m | 45.00 | -- | 1.47 | -- | 0.7763 | -0.2377 | -0.2377 | 1.20 | 0.6333 | 0.8388 | -- | 8.85 | 968,704.60 | -16.37 | -46.81 | -29.58 | -57.36 | -- | -- | -19.52 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
Ocuphire Pharma Inc | 16.45m | -14.11m | 33.27m | 14.00 | -- | 0.8119 | -- | 2.02 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.42m | 3.38% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.01m | 1.00% |
AMH Equity Ltd.as of 30 Jun 2024 | 923.62k | 0.91% |
Renaissance Technologies LLCas of 30 Jun 2024 | 778.70k | 0.77% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 381.29k | 0.38% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 247.71k | 0.25% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 183.30k | 0.18% |
Citadel Securities LLCas of 31 Mar 2024 | 161.28k | 0.16% |
T. Rowe Price International Ltd.as of 31 Mar 2024 | 125.90k | 0.13% |
Commonwealth Equity Services LLCas of 30 Jun 2024 | 45.93k | 0.05% |